Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Jun 4, 2022--
NEW YORK--(BUSINESS WIRE)--Jun 4, 2022--